Study identifier:D2287R00102
ClinicalTrials.gov identifier:NCT02600221
EudraCT identifier:N/A
CTIS identifier:N/A
A non-interventional study to investigate the current situation of Asthma-COPD Overlap Syndrome in patients over age 40 with persistent airflow limitation in China
Asthma-COPD Overlap Syndrome
N/A
No
-
All
2016
Observational
40 Years +
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: Open Label
Primary Purpose: -
Verified 01 Oct 2017 by AstraZeneca
AstraZeneca
-
To investigate the distributions of the patients with ACOS, asthma and COPD over age 40 with chronic airflow limitation in China.
Sites must be tier 3 hospitals in China. Investigators will mainly be determined according to the following criteria: •Respiratory physicians working in the respiratory department of tier 3 hospitals •To include the expected number of patients in a maximum of 12 months, physicians should manage a reasonable number of asthma, COPD or ACOS over age 40 with persistent airflow limitation (post-BD FEV1/FVC<0.7). •Physicians should have patients’ spirometric data available in the patient’s medical files (post-BD FEV1%pred and post-BD FEV1/FVC). This NIS will collect the data (e.g. medical record, patient or physician-reported data) from about 2000 consecutive outpatients with persistent airflow limitation(post-BD FEV1/FVC<0.7) in about 20 sites in China for one year. Each site will recruit about 50-150 patients successively. The data will be collected under routine clinical practice. The treatments or examinations will be determined by their treating physicians. The data are expected to reflect the actual situation about ACOS. The study population will be about 2000 outpatients, men or women, over age 40, with a clinical diagnosis of asthma, COPD or ACOS with persistent airflow limitation(post-BD FEV1/FVC<0.7)in China from Q4,2015 to Q3,2016.
Location
Location
Shenyang, Liaoning, China
Location
Shenyang, Liaoning, China
Location
Beijing, Beijing, China
Location
Chengdou, Sichuan, China
Location
Guangzhou, Guangdong, China
Location
Shanghai, Shanghai, China
Location
Beijing, Beijing, China
Location
Zhengzhou, Henan, China
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.